CREATE Medicines

Company Overview

A clinical-stage biotechnology company deploying mRNA-LNP technology to engineer CAR-expressing immune cells directly inside the body, bypassing the manufacturing bottlenecks that have constrained ex vivo cell therapy for a decade. CREATE Medicines uses lipid nanoparticles loaded with mRNA to instruct T cells, NK cells, and myeloid cells in vivo to express chimeric antigen receptors — no leukapheresis, no cleanroom manufacturing, no weeks-long patient wait. The approach is designed to be repeat-dosable and off-the-shelf, two properties that approved CAR-T products cannot offer. With more than 50 patients dosed across its clinical programs, CREATE claims the largest in vivo CAR dataset yet assembled.

Headquarters and Global Presence

CREATE Medicines is headquartered in Cambridge, Massachusetts, the dense biotech corridor that gives it proximity to academic medical centers running its clinical trials. The company operates as a focused clinical-stage entity without disclosed international manufacturing sites.

Founding and History

CREATE Medicines was co-founded by Daniel Getts, Ph.D., drawing on his background in immunology and RNA biology to address the scalability limits of first-generation CAR-T. The company progressed from preclinical work to clinical dosing and has built what it describes as the field's most extensive in vivo CAR clinical dataset. In May 2026, it closed a $122 million Series B, its most significant financing to date, to accelerate programs across oncology and autoimmunity.

Therapy Areas and Focus

CREATE targets three broad disease categories: cancer (solid tumors and hematologic malignancies), autoimmune disease, and fibrosis. The autoimmunity expansion is strategically significant — the success of ex vivo CAR-T in conditions like lupus and myositis has opened a large addressable market that the complexity of current manufacturing has kept inaccessible at scale. Solid tumor CAR-T remains the hardest problem in cell therapy; CREATE's multi-cell-type targeting strategy is one answer to the immunosuppressive tumor microenvironment that has blunted single-agent CAR-T in solid cancers.

Technology Platforms and Modalities

The core platform delivers mRNA encoding a CAR construct via lipid nanoparticles optimized for immune cell tropism — a meaningfully different engineering challenge from the liver-targeted LNPs used in RNA vaccines. By programming T cells, NK cells, and myeloid cells simultaneously or selectively, CREATE can potentially address tumor heterogeneity and the suppressive microenvironment in ways that a T-cell-only approach cannot. The transient expression kinetics of mRNA mean CAR activity is time-limited per dose, which has safety implications but also creates a rational basis for repeat dosing to maintain efficacy. That repeat-dose profile is arguably the platform's most commercially interesting feature relative to the single-administration paradigm of current approved therapies.

Key Pipeline and Programs

CREATE has not publicly disclosed individual asset names or IND numbers from the available research, but its clinical activity spans oncology and autoimmune disease indications with more than 50 patients dosed across programs — a dataset the company argues is unmatched in the in vivo CAR field.

In oncology, programs address both solid tumors and hematologic malignancies. The multi-cell targeting strategy — co-programming T cells and NK cells or myeloid cells — is central to the solid tumor approach, designed to overcome the antigen escape and microenvironmental suppression that has limited prior CAR-T efforts in these cancers.

In autoimmunity, CREATE is advancing in vivo CAR programs that exploit the same regulatory B-cell and pathogenic lymphocyte biology that has made ex vivo CAR-T a surprise success in refractory systemic autoimmune conditions. The in vivo route, if validated, would make this therapeutic logic accessible at a fraction of current cost and logistical complexity.

The $122 million Series B is earmarked specifically to advance these clinical programs, suggesting near-term trial expansion and potential data readouts across both franchises.

Recent Developments

On May 14, 2026, CREATE closed a $122 million Series B co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with Alexandria Venture Investments among participating investors. Concurrent with the raise, Ron Philip — previously CEO of Orbital Therapeutics and a senior executive at Spark Therapeutics — joined the company as executive chairman, a hire that signals preparation for a more visible clinical and potentially commercial phase. The milestone of 50-plus patients dosed across in vivo CAR programs, disclosed alongside the financing, is the company's most substantive clinical proof-of-concept signal to date.

Key Personnel

Daniel Getts, Ph.D. serves as Chief Executive Officer, Co-founder, and Board Director. His background spans immunology and RNA biology, and he has guided CREATE from founding through its first clinical dataset of more than 50 dosed patients. Ron Philip joined as Executive Chairman in May 2026; he previously served as CEO of Orbital Therapeutics and held leadership roles at Spark Therapeutics, bringing gene and RNA therapy commercialization experience directly relevant to CREATE's platform trajectory.

Strategic Partnerships

The Series B syndicate — anchored by ARCH Venture Partners, Newpath Partners, Hatteras Venture Partners, and Alexandria Venture Investments — represents the most visible strategic backing disclosed. No third-party licensing or co-development partnerships with large pharma have been announced to date, leaving CREATE as an independently advancing clinical-stage entity with its pipeline intact.

FAQ Section